加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.83
+US$0.02 · +1.10%
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
前收盘价
US$1.83
+US$0.02 · +1.10%
盘中时间采用ET。市场数据可能有所延迟。
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
日内区间
当前US$1.83
52周区间
当前US$1.83
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
56
多空交织
风险
89
极高风险
动量
20
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
日内区间
当前US$1.83
52周区间
当前US$1.83
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7000万 USD | — | — | — | — |
| 销货成本 | 32.5万 USD | — | 43.7万 USD | — | — |
| 毛利 | 6967.5万 USD | — | −43.7万 USD | — | — |
| 研究与开发 | 3355.8万 USD | 5131.2万 USD | 5891.3万 USD | 6443.7万 USD | 9682.9万 USD |
| 销售、一般及管理费用 | 1657.2万 USD | 2746.9万 USD | 2711万 USD | 2839.1万 USD | 3004.3万 USD |
| 营业费用 | 4980.5万 USD | 7878.1万 USD | 8602.3万 USD | 9282.8万 USD | 1.27亿 USD |
| 利息收入 | 406.1万 USD | 218.2万 USD | 192.4万 USD | 203.1万 USD | 346.4万 USD |
| 折旧和摊销 | 32.5万 USD | 34.3万 USD | 43.7万 USD | 50.8万 USD | 20.5万 USD |
| 营业利润 | 1987万 USD | −7878.1万 USD | −8646万 USD | −9282.8万 USD | −1.27亿 USD |
| 净利润 | 2236.7万 USD | −6967.6万 USD | −8244.2万 USD | −9116.9万 USD | −1.26亿 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI326.81万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM223.66万0.00%787.4亿 USD0.19%US$278.94+0.49%
Fidelity Enhanced Small Cap ETFFESM113.74万0.02%64.1亿 USD0.28%US$45.46+0.46%
Vanguard Extended Market ETFVXF107.36万0.00%954亿 USD0.05%US$235+0.80%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV97.91万0.00%268.09亿 USD0.33%US$37.95-0.39%
iShares Biotechnology ETFIBB68.94万0.01%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO57.18万0.00%180亿 USD0.06%US$112.66+0.50%
EA Bridgeway Omni Small-Cap Value ETFBSVO51万0.02%23.91亿 USD0.45%US$28.37-0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOEA Bridgeway Omni Small-Cap Value ETFBSVOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
